## **Re: Your request made under the Freedom of Information Act 2000**

I've got a Freedom of Information query that I hope you'll be able to help me with

1) Within the last 2 years, has the institution accepted or is it currently accepting any of the following drugs free of charge or for a nominal charge (eg £1):

Rizankizumab (Skyrizi): not on Trust Formulary, never been requested.

Guselkumab (Tremfya): In use within Trust - no early access pricing agreement signed.

Brodalumab (Kyntheum): In use within Trust – no early access pricing agreement signed.

Ixekizumab (Taltz): In use within Trust – signed early access pricing agreement but no eligible patients registered during the agreement period – pricing applied to the first five doses (first three months treatment).

Secukinumab (Cosentyx): In use within Trust - no early access pricing agreement signed.

Tildrakizumab (Ilumetri): In use within Trust - no early access pricing agreement signed.

2) If yes to any of the above, are you able to say how long is the free of charge drug stock typically provided for each patient? For example, is it:

First dose First month First 3 months Some other period?

See Taltz entry (Q1)

3) If the Institution has not accepted manufacturer provision of free of charge drug stock, are you able to say what have been the reasons for this?

Following Regional Pharmacy Procurement Specialist advice and issues around recharging/refunding the CCG's.